The effect of desacetyluvaricin on the expression of TLR4 and P53 protein in Hepg 2.2.15

authors:

avatar Hai Bin He 1 , avatar Xian Lin Wu 2 , * , avatar Bin Yu 3 , avatar Kang Li Liu 3 , avatar Guang Xiong Zhou 3 , avatar Guo Qiang Qian 3 , avatar Da Hong Ju 4 , avatar Xiao Yin Chen 5 , **

Department of Gastroenterology, the Peoples Hospital of Heshan, China
Department of Traditional Chinese Medicine, Medicine College of Jinan University, China
Department of Traditional Chinese Medicine, Medicine College of Jinan University, China
Institute of Basic Theories of Traditional Chinese Medicine, China Academy of Traditional Chinese Medicine, China
Department of Traditional Chinese Medicine, Medicine College of Jinan University, [email protected], China
Corresponding Authors:

how to cite: He H, Wu X, Yu B, Liu K, Zhou G, et al. The effect of desacetyluvaricin on the expression of TLR4 and P53 protein in Hepg 2.2.15. Hepat Mon.11(5): 364-367.

Abstract

Background: Previous studies suggest that annonaceous may cause permeability glycoprotein (P-gp) function to abate, leading to cell apoptosis. It has also been reported that annonaceous acetogenins affect hepatocellular carcinoma (HCC) cells in the G1 phase, leading to apoptosis. Desacetyluvaricin (Des), a new type of annonaceous acetogenin monomer, has a significant effect on HCC, with few side effects.
Objectives: To investigate the effect of Des on the expression of Toll-like receptor 4 (TLR4) and P53 protein in HCC.
Materials and Methods: HCC HepG2.2.15 cell was cultured by routine method. HepG2.2.15 cells were divided into three groups: control group, treated with Des and DDP (cisplatin) which were examined by immunofluorescence flow cytometry for expression of TLR4 and P53.
Results: TLR4 was expressed by more cells in the Des group than in the cisplatin or serum-only groups (71.94%, 42.64%, and 37.16%, respectively; Des vs.cisplatin: p < 0.05; Des vs. serum only: p < 0.05), with no difference between the cisplatin and serum-only groups (p > 0.05). P53 was expressed by more cells in the Des and cisplatin groups than in the serum-only group (32.6%, 31.5% and 3.3%, respectively; Des vs. serum only, p < 0.05; cisplatin vs. serum only, p < 0.05), with no difference between the Des and cisplatin groups (p > 0.05).
Conclusions: Des increases TLR4 and P53 expression in HCC cells. Improved immune recognition by the former effect and induction of apoptosis by the latter could be the mechanisms of Des's clinical effects on HCC.
Keywords: Desacetyluvaricin; TLR4 receptor; P53 tumor suppressor protein; Flow cytometry; Hepatocellular carcinoma


  • Implication for health policy/practice/research/medical education:
    Finding new molecular methods for diagnosis and treating HCC has highly degree of attention when other researchers try to follow and complete a unique strategy. Reading this article is recommended to oncologists, hepatologists and molecular genticians.
  • Please cite this paper as:
    He HB, Wu XL, Yu B, Liu KL, Zhou GX, Qian GQ, et al. The effect of desacetyluvaricin on the expression of TLR4 and P53 protein in Hepg2.2.15. Hepat Mon.2011;11(5):364-367.

2011 Kowsar M.P.Co. All rights reserved.


Full Text

Full text is available in PDF

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.